

## Datasheet: HCA380

**BATCH NUMBER 166024**

<b>Description:</b>	HUMAN ANTI ATEZOLIZUMAB
<b>Specificity:</b>	ATEZOLIZUMAB
<b>Other names:</b>	Tecentriq
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD41002ia
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Product Form</b>	Human IgG1 antibody (kappa light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A
<b>Source</b>	HKB-11
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.09% Sodium Azide (NaN <sub>3</sub> )
<b>Approx. Protein Concentrations</b>	Antibody concentration 0.5 mg/ml
<b>Immunogen</b>	Atezolizumab

**Specificity**

**Human Anti-Atezolizumab Antibody, clone AbD41002ia** is a paratope specific, inhibitory anti-idiotypic antibody (Type 1) that specifically recognizes the free monoclonal antibody drug atezolizumab. This is a humanized, Fc-engineered IgG1/kappa antibody with allotype nG1m1. The CH2 domain was engineered with one amino acid substitution (N298A) resulting in a non-glycosylated antibody, to impair Fcγ receptor binding and to prevent Fc-mediated depletion of cells expressing PD-L1. The antibody does not recognize free PD-L1 nor atezolizumab in complex with PD-L1.

Clone AbD41002ia is a fully human recombinant monoclonal antibody with IgG1 isotype and can be used as a surrogate positive control or reference standard in an anti-drug antibody (ADA) assay. This antibody has a monovalent intrinsic affinity of 16 nM, and is one of three Type 1 antibodies with different affinities offered for ADA assays.

[ADA bridging ELISA](#)

Atezolizumab (Tecentriq) is a human monoclonal IgG1 antibody that binds directly to Programmed Death Ligand 1 (PD-L1, CD274) and provides a dual blockade of both the PD-1 and B7.1 receptors on T-cells and antigen presenting cells. It is one of the named “checkpoint inhibitor” drugs. PD-L1/PD-1 mediated inhibition of the immune response is thereby released, including reactivation of the anti-tumour immune response without induction of antibody-dependent cellular cytotoxicity. The drug is used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer and hepatocellular carcinoma. It is used either on its own or in combination for cancers which are advanced or metastatic.

[View a summary of all anti-atezolizumab antibodies](#)

---

**Affinity**

The intrinsic affinity of the monovalent form of Human anti Atezolizumab antibody, clone AbD41002ia is  $K_D = 16$  nM as measured by real time, label free molecular interaction analysis on immobilized Atezolizumab.

---

**ELISA**

Human anti Atezolizumab antibody, clone AbD41002ia can be used as a calibrator in an anti-drug antibody assay.

Protocol: [ADA bridging ELISA](#).

---

**Storage**

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

---

**Guarantee**

12 months from date of despatch

---

**Acknowledgements**

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See [bio-rad.com/en-us/trademarks](http://bio-rad.com/en-us/trademarks) for details.

Tecentriq is a trademark of Roche/ Genentech.

---

**Health And Safety Information** Material Safety Datasheet documentation #10040 available at:  
<https://www.bio-rad-antibodies.com/SDS/HCA380>  
10040

---

**Licensed Use** For *in vitro* research purposes and for commercial applications for the provision of *in vitro* testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

---

**Regulatory** For research purposes only

---

**Technical Advice** Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#).

---

## Related Products

### Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HUMAN ANTI ATEZOLIZUMAB \(HCA381\)](#)

[HUMAN ANTI ATEZOLIZUMAB \(HCA382\)](#)

[HUMAN ANTI ATEZOLIZUMAB \(TZA011\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)  
'M421770:230725'

**Printed on 01 Mar 2024**

---

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)